- Conditions
- PTSD
- Interventions
- Moderate Intensity Exercise, Low Intensity Exercise
- Behavioral
- Lead sponsor
- Christal L Badour
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tinnitus
- Interventions
- IV Lidocaine
- Drug
- Lead sponsor
- D. Bradley Welling, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Control in Premature Infants
- Interventions
- Bedside Physiology study, Carotid Body Function Test, Room Air Challenge, Hypoxia Challenge Test, Effects of Nasal Cannula Flow, Magnetic Resonance Imaging, Echocardiogram, Blood Sample
- Other · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Day to 28 Days
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer
- Interventions
- F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Mild Cognitive Impairment
- Interventions
- Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Interventions
- Intensity Modulated Radiotherapy (IMRT), Cisplatin, Limited surgical evaluation
- Radiation · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Gainesville, Florida • Chapel Hill, North Carolina + 1 more
- Conditions
- Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
- Interventions
- Cognitive Testing, MRI, PET
- Behavioral · Other · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metabolic Syndrome, Lipotoxicity
- Interventions
- Valsartan, Hydrochlorothiazide
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stroke
- Interventions
- tDCS: noninvasive brain stimulation, Constraint induced movement therapy (CIMT), Sham tDCS: placebo noninvasive brain stimulation
- Procedure · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Healthy, Covert Consciousness
- Interventions
- Dexmedetomidine (+propofol as indicated), Ketamine
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Epilepsy, Generalized, Memory Impairment
- Interventions
- Supervised combined endurance and resistance training (CERT), Delayed supervised combined endurance and resistance training (CERT)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Vasculitis, CNS, Vasculitis, Cerebral
- Interventions
- MRI, including intracranial vessel wall imaging
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sepsis, Septic Shock
- Interventions
- Not listed
- Lead sponsor
- Bluejay Diagnostics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
- Conditions
- Safety and Efficacy of Sedation Medications
- Interventions
- Dexmedetomidine, Propofol
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT)
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Vincristine Sulfate, Vinorelbine Tartrate, X-Ray Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 50 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 228
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 160 more
- Conditions
- Perception of Things Changing Color, Adaptive Behavior
- Interventions
- Mode Switching Training
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Bladder Cancer Stage II
- Interventions
- MRI imaging of the pelvis/bladder, genomic analysis of tumor
- Diagnostic Test
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
- Interventions
- E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Anesthesia, Healthy
- Interventions
- Dexmedetomidine, Saline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Aging, Exercise
- Interventions
- Stretching Exercise Intervention, Aerobic Exercise Intervention, Self Monitoring
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Glymphatic Flow
- Interventions
- Brain connectivity and physiology, Dexmedetomidine
- Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 20 Years to 40 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more